In gastric cancer, NUTM2A-AS1 contributes to matrine resistance by forming a regulatory axis with miR-613 and VEGFA, where its knockdown decreases cell viability, reduces proliferation, and enhances apoptosis in tandem with altered ROS, glutathione levels, and superoxide dismutase activity [52]. This evidence concerns the gene NUTM2A and gastric cancer.